WEDNESDAY, Sept. 28, 2022 (HealthDay) — Japanese drugmaker Eisai on Wednesday said its experimental drug lecanemab helped slow thinking declines among people in the early stages of Alzheimer’s disease. The findings from a phase 3 clinical trial have yet to be peer-reviewed in any medical journal. But according to aContinue Reading

FRIDAY, Sept. 16, 2022 (HealthDay News) — COVID-19 infection may significantly boost an older person’s risk of developing Alzheimer’s disease, a new, large-scale study suggests. People 65 and older who contracted COVID were nearly 70% more likely overall to be diagnosed with Alzheimer’s within a year of their infection, researchersContinue Reading

TUESDAY, Aug. 9, 2022 (HealthDay News) — Rural Americans with early-onset Alzheimer’s disease are less likely than city dwellers to see a specialist and undergo tests that can help them and their families manage, new research reveals. While most Alzheimer’s patients are over 65, about 6% develop the disease betweenContinue Reading